Long Intergenic Noncoding RNA 00511 Acts as an Oncogene in Non–small-cell Lung Cancer by Binding to EZH2 and Suppressing p57

Molecular Therapy Nucleic Acids

Volumn 5, Issue , 2016, Pages e385-

  Sun, Cheng Cao ^a   Li, Shu Jun ^a,b   Li, Guang ^c   Hua, Rui Xi ^d   Zhou, Xu Hong ^a   Li, De Jia ^a  

^a WUHAN UNIVERSITY   (China)

^b Center for Disease Control and Prevention of Wuhan   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

enhancer of zeste homolog 2; long noncoding RNA LINC00511; non small cell lung cancer; p57; polycomb repressive complex 2; tumorigenesis

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1C; HISTONE H3; LONG INTERGENIC NONCODING RNA; LONG UNTRANSLATED RNA; LYSINE; MICRORNA; POLYCOMB REPRESSIVE COMPLEX 2; RNA BINDING PROTEIN; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; LONG INTERGENIC NONCODING RNA 00511;

A-549 CELL LINE; AGED; APOPTOSIS; ARTICLE; CANCER CELL LINE; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CARCINOGENESIS; CELL DEATH; CELL INVASION; CELL LYSATE; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVE SITE; FEMALE; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; GENE REPRESSION; GENE SILENCING; GENE TARGETING; HISTONE MODIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE METASTASIS; MALE; METASTASIS; NON SMALL CELL LUNG CANCER; ONCOGENE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME; TUNEL ASSAY; UPREGULATION; ADULT; ANIMAL MODEL; CELL GROWTH; COMPLEX FORMATION; CYTOLOGY; ELECTIVE SURGERY; GENE EXPRESSION; HISTONE METHYLATION; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; MAJOR CLINICAL STUDY; MIDDLE AGED; MOUSE; NONHUMAN; SQUAMOUS CELL LUNG CARCINOMA; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT;

EID: 85015173276     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2016.94     Document Type: Article

References (55)

1. 1 DeSantis, CE, Lin, CC, Mariotto, AB, Siegel, RL, Stein, KD, Kramer, JL, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 64 (2014), 252–271.
2. 2 Sanoff, HK, Sargent, DJ, Campbell, ME, Morton, RF, Fuchs, CS, Ramanathan, RK, et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol 26 (2008), 5721–5727.
3. 3 Sung, JJ, Ng, SC, Chan, FK, Chiu, HM, Kim, HS, Matsuda, T, et al., Asia Pacific Working Group, An updated Asia Pacific Consensus Recommendations on colorectal cancer screening. Gut 64 (2015), 121–132.
4. 4 Torre, LA, Bray, F, Siegel, RL, Ferlay, J, Lortet-Tieulent, J, Jemal, A, Global cancer statistics, 2012. CA Cancer J Clin 65 (2015), 87–108.
5. 5 De Rosa, M, Pace, U, Rega, D, Costabile, V, Duraturo, F, Izzo, P, et al. Genetics, diagnosis and management of colorectal cancer (Review). Oncol Rep 34 (2015), 1087–1096.
6. 6 Sung, JJ, Lau, JY, Young, GP, Sano, Y, Chiu, HM, Byeon, JS, et al., Asia Pacific Working Group on Colorectal Cancer, Asia Pacific consensus recommendations for colorectal cancer screening. Gut 57 (2008), 1166–1176.
7. 7 Rerknimitr, R, Angsuwatcharakon, P, Ratanachu-ek, T, Khor, CJ, Ponnudurai, R, Moon, JH, et al., Asia-Pacific Working Group on Hepatobiliary Cancers, Asia-Pacific consensus recommendations for endoscopic and interventional management of hilar cholangiocarcinoma. J Gastroenterol Hepatol 28 (2013), 593–607.
8. 8 Mercer, TR, Dinger, ME, Mattick, JS, Long non-coding RNAs: insights into functions. Nat Rev Genet 10 (2009), 155–159.
9. 9 Ørom, UA, Derrien, T, Beringer, M, Gumireddy, K, Gardini, A, Bussotti, G, et al. Long noncoding RNAs with enhancer-like function in human cells. Cell 143 (2010), 46–58.
10. 10 Huarte, M, Guttman, M, Feldser, D, Garber, M, Koziol, MJ, Kenzelmann-Broz, D, et al. A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell 142 (2010), 409–419.
11. 11 Geisler, S, Lojek, L, Khalil, AM, Baker, KE, Coller, J, Decapping of long noncoding RNAs regulates inducible genes. Mol Cell 45 (2012), 279–291.
12. 12 Rinn, JL, Kertesz, M, Wang, JK, Squazzo, SL, Xu, X, Brugmann, SA, et al. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell 129 (2007), 1311–1323.
13. 13 Pandey, GK, Mitra, S, Subhash, S, Hertwig, F, Kanduri, M, Mishra, K, et al. The risk-associated long noncoding RNA NBAT-1 controls neuroblastoma progression by regulating cell proliferation and neuronal differentiation. Cancer Cell 26 (2014), 722–737.
14. 14 Garzon, R, Volinia, S, Papaioannou, D, Nicolet, D, Kohlschmidt, J, Yan, PS, et al. Expression and prognostic impact of lncRNAs in acute myeloid leukemia. Proc Natl Acad Sci USA 111 (2014), 18679–18684.
15. 15 Yang, F, Huo, XS, Yuan, SX, Zhang, L, Zhou, WP, Wang, F, et al. Repression of the long noncoding RNA-LET by histone deacetylase 3 contributes to hypoxia-mediated metastasis. Mol Cell 49 (2013), 1083–1096.
16. 16 Barnhill, LM, Williams, RT, Cohen, O, Kim, Y, Batova, A, Mielke, JA, et al. High expression of CAI2, a 9p21-embedded long noncoding RNA, contributes to advanced-stage neuroblastoma. Cancer Res 74 (2014), 3753–3763.
17. 17 Yang, F, Zhang, L, Huo, XS, Yuan, JH, Xu, D, Yuan, SX, et al. Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans. Hepatology 54 (2011), 1679–1689.
18. 18 Prensner, JR, Iyer, MK, Balbin, OA, Dhanasekaran, SM, Cao, Q, Brenner, JC, et al. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol 29 (2011), 742–749.
19. 19 Yang, F, Zhang, L, Huo, XS, Yuan, JH, Xu, D, Yuan, SX, et al. Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans. Hepatology 54 (2011), 1679–1689.
20. 20 Wang, F, Yuan, JH, Wang, SB, Yang, F, Yuan, SX, Ye, C, et al. Oncofetal long noncoding RNA PVT1 promotes proliferation and stem cell-like property of hepatocellular carcinoma cells by stabilizing NOP2. Hepatology 60 (2014), 1278–1290.
21. 21 Yuan, SX, Wang, J, Yang, F, Tao, QF, Zhang, J, Wang, LL, et al. Long noncoding RNA DANCR increases stemness features of hepatocellular carcinoma by derepression of CTNNB1. Hepatology 63 (2016), 499–511.
22. 22 Yuan, SX, Yang, F, Yang, Y, Tao, QF, Zhang, J, Huang, G, et al. Long noncoding RNA associated with microvascular invasion in hepatocellular carcinoma promotes angiogenesis and serves as a predictor for hepatocellular carcinoma patients’ poor recurrence-free survival after hepatectomy. Hepatology 56 (2012), 2231–2241.
23. 23 Yap, KL, Li, S, Muñoz-Cabello, AM, Raguz, S, Zeng, L, Mujtaba, S, et al. Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell 38 (2010), 662–674.
24. 24 Pasmant, E, Laurendeau, I, Héron, D, Vidaud, M, Vidaud, D, Bièche, I, Characterization of a germ-line deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF. Cancer Res 67 (2007), 3963–3969.
25. 25 Gupta, RA, Shah, N, Wang, KC, Kim, J, Horlings, HM, Wong, DJ, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 464 (2010), 1071–1076.
26. 26 Wang, KC, Chang, HY, Molecular mechanisms of long noncoding RNAs. Mol Cell 43 (2011), 904–914.
27. 27 Tsai, MC, Manor, O, Wan, Y, Mosammaparast, N, Wang, JK, Lan, F, et al. Long noncoding RNA as modular scaffold of histone modification complexes. Science 329 (2010), 689–693.
28. 28 Yuan, JH, Yang, F, Wang, F, Ma, JZ, Guo, YJ, Tao, QF, et al. A long noncoding RNA activated by TGF-β promotes the invasion-metastasis cascade in hepatocellular carcinoma. Cancer Cell 25 (2014), 666–681.
29. 29 de Kok, JB, Verhaegh, GW, Roelofs, RW, Hessels, D, Kiemeney, LA, Aalders, TW, et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 62 (2002), 2695–2698.
30. 30 Sun, C, Li, S, Zhang, F, Xi, Y, Wang, L, Bi, Y, et al. Long non-coding RNA NEAT1 promotes non-small cell lung cancer progression through regulation of miR-377-3p-E2F3 pathway. Oncotarget 7 (2016), 51784–51814.
31. 31 Zequn, N, Xuemei, Z, Wei, L, Zongjuan, M, Yujie, Z, Yanli, H, et al. The role and potential mechanisms of LncRNA-TATDN1 on metastasis and invasion of non-small cell lung cancer. Oncotarget 7 (2016), 18219–18228.
32. 32 Chen, Z, Li, JL, Lin, S, Cao, C, Gimbrone, NT, Yang, R, et al. cAMP/CREB-regulated LINC00473 marks LKB1-inactivated lung cancer and mediates tumor growth. J Clin Invest 126 (2016), 2267–2279.
33. 33 Li, W, Sun, M, Zang, C, Ma, P, He, J, Zhang, M, et al. Upregulated long non-coding RNA AGAP2-AS1 represses LATS2 and KLF2 expression through interacting with EZH2 and LSD1 in non-small-cell lung cancer cells. Cell Death Dis, 7, 2016, e2225.
34. 34 Pan, H, et al. Long non-coding RNA BC087858 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell lung cancer. Oncotarget 7 (2016), 49948–49960.
35. 35 Zang, C, Nie, FQ, Wang, Q, Sun, M, Li, W, He, J, et al. Long non-coding RNA LINC01133 represses KLF2, P21 and E-cadherin transcription through binding with EZH2, LSD1 in non small cell lung cancer. Oncotarget 7 (2016), 11696–11707.
36. 36 Huang, YS, Chang, CC, Lee, SS, Jou, YS, Shih, HM, Xist reduction in breast cancer upregulates AKT phosphorylation via HDAC3-mediated repression of PHLPP1 expression. Oncotarget 7 (2016), 43256–43266.
37. 37 Zou, P, Yoshihara, H, Hosokawa, K, Tai, I, Shinmyozu, K, Tsukahara, F, et al. p57(Kip2) and p27(Kip1) cooperate to maintain hematopoietic stem cell quiescence through interactions with Hsc70. Cell Stem Cell 9 (2011), 247–261.
38. 38 Avrahami, D, Li, C, Yu, M, Jiao, Y, Zhang, J, Naji, A, et al. Targeting the cell cycle inhibitor p57Kip2 promotes adult human β cell replication. J Clin Invest 124 (2014), 670–674.
39. 39 Naito, M, Mori, M, Inagawa, M, Miyata, K, Hashimoto, N, Tanaka, S, et al. Dnmt3a regulates proliferation of muscle satellite cells via p57Kip2. PLoS Genet, 12, 2016, e1006167.
40. 40 Sun, CC, Li, SJ, Li, DJ, Hsa-miR-134 suppresses non-small cell lung cancer (NSCLC) development through down-regulation of CCND1. Oncotarget 7 (2016), 35960–35978.
41. 41 Sun, C, Huang, C, Li, S, Yang, C, Xi, Y, Wang, L, et al. Hsa-miR-326 targets CCND1 and inhibits non-small cell lung cancer development. Oncotarget 7 (2016), 8341–8359.
42. 42 Nie, F, Yu, X, Huang, M, Wang, Y, Xie, M, Ma, H, et al. Long noncoding RNA ZFAS1 promotes gastric cancer cells proliferation by epigenetically repressing KLF2 and NKD2 expression. Oncotarget, 2016 epub ahead of print.
43. 43 Guo, J, Cai, J, Yu, L, Tang, H, Chen, C, Wang, Z, EZH2 regulates expression of p57 and contributes to progression of ovarian cancer in vitro and in vivo. Cancer Sci 102 (2011), 530–539.
44. 44 Yang, X, Karuturi, RK, Sun, F, Aau, M, Yu, K, Shao, R, et al. CDKN1C (p57) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells. PLoS One, 4, 2009, e5011.
45. 45 Oh, TG, Wang, SC, Acharya, BR, Goode, JM, Graham, JD, Clarke, CL, et al. The nuclear receptor, RORγ, regulates pathways necessary for breast cancer metastasis. EBioMedicine 6 (2016), 59–72.
46. 46 Yang, F, Lyu, S, Dong, S, Liu, Y, Zhang, X, Wang, O, Expression profile analysis of long noncoding RNA in HER-2-enriched subtype breast cancer by next-generation sequencing and bioinformatics. Onco Targets Ther 9 (2016), 761–772.
47. 47 Sun, C, Yang, C, Xue, R, Li, S, Zhang, T, Pan, L, et al. Sulforaphane alleviates muscular dystrophy in mdx mice by activation of Nrf2. J Appl Physiol (1985) 118 (2015), 224–237.
48. 48 Sun, CC, Li, SJ, Yang, CL, Xue, RL, Xi, YY, Wang, L, et al. Sulforaphane attenuates muscle inflammation in dystrophin-deficient mdx mice via NF-E2-related factor 2 (Nrf2)-mediated inhibition of NF-κB signaling pathway. J Biol Chem 290 (2015), 17784–17795.
49. 49 Sun, C, Li, S, Li, D, Sulforaphane mitigates muscle fibrosis in mdx mice via Nrf2-mediated inhibition of TGF-β/Smad signaling. J Appl Physiol (1985) 120 (2016), 377–390.
50. 50 Sun, C, Liu, Z, Li, S, Yang, C, Xue, R, Xi, Y, et al. Down-regulation of c-Met and Bcl2 by microRNA-206, activates apoptosis, and inhibits tumor cell proliferation, migration and colony formation. Oncotarget 6 (2015), 25533–25574.
51. 51 Sun, C, Sang, M, Li, S, Sun, X, Yang, C, Xi, Y, et al. Hsa-miR-139-5p inhibits proliferation and causes apoptosis associated with down-regulation of c-Met. Oncotarget 6 (2015), 39756–39792.
52. 52 Sun, CC, Li, SJ, Li, DJ, Hsa-miR-134 suppresses non-small cell lung cancer (NSCLC) development through down-regulation of CCND1. Oncotarget 7 (2016), 35960–35978.
53. 53 Sun, C, Huang, C, Li, S, Yang, C, Xi, Y, Wang, L, et al. Hsa-miR-326 targets CCND1 and inhibits non-small cell lung cancer development. Oncotarget 7 (2016), 8341–8359.
54. 54 Sun, CC, Li, SJ, Zhang, F, Pan, JY, Wang, L, Yang, CL, et al. Hsa-miR-329 exerts tumor suppressor function through down-regulation of MET in non-small cell lung cancer. Oncotarget 7 (2016), 21510–21526.
55. 55 Sun, C, Li, S, Yang, C, Xi, Y, Wang, L, Zhang, F, et al. MicroRNA-187-3p mitigates non-small cell lung cancer (NSCLC) development through down-regulation of BCL6. Biochem Biophys Res Commun 471 (2016), 82–88.